Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda - Takeaway - MDSpire
Feature

Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included

  • April 9, 2026

  • 2 min

Share

  • 1

    Gene therapy for sickle cell disease (SCD) is being assessed for affordability in Uganda.

  • 2

    The study adapts U.S. economic models to Uganda's context.

  • 3

    Uganda's lifetime SCD care cost is $21,877 vs over $600,000 in the U.S.

  • 4

    Casgevy is found more cost-effective compared to Lyfgenia.

  • 5

    Affordability hinges on dramatic price reductions.

  • 6

    Societal benefits like productivity and caregiver burden are crucial.

  • 7

    The study aids policymakers in improving access to gene therapy.

Original Source(s)

Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

  • April 9, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...